Date: 2015-09-23
Type of information: Nomination
Compound:
Company: Promethera Biosciences (Belgium)
Therapeutic area: Genetic diseases - Hepatic diseases - Liver diseases -
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 23, 2015, Promethera Biosciences, a Belgian biotechnology company developing HepaStem, a cell-based therapy for the treatment of inborn errors of metabolism and acquired liver diseases, has appointed Dr John Tchelingerian as its new Chief Executive Officer. John Tchelingerian joined the company as Chairman of the Board on 8 December, 2014, and has acted as its interim CEO since 23 January, 2015.
Financial terms:
Latest news:
